Company intelligence / Profile preview

MedTrace Pharma

Ownership: Private
Development stage: Phase 3

Overview

The company’s lead program (^15O-water PET) has dosed over 2000 patients across Denmark, Sweden, and the US under research or exemption protocols. The pivotal RAPID-WATER-FLOW Phase 3 trial aims to demonstrate diagnostic accuracy/safety of ^15O-water PET for coronary artery disease. Early results have enabled first-in-US patient dosing using their automated system. aQuant software automates quantitative image analysis but remains pre-market approval.

Therapeutic areas: OncologyEndocrinologyCardiovascular
Modalities: RadiopharmaceuticalDeviceSoftware
Industry: Biotech

Drug pipeline

1 asset

15O-water

Partnerships

Brigham and Women’s Hospital / Harvard Medical School (RAPID-WATER-FLOW trial)Aarhus University Hospital DenmarkaQuant team/software founders (merged in 2018)

Beyond the preview

Go deeper on MedTrace Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedTrace Pharma.

Explore the full profile